1	Title: Influenza-Negative Influenza-Like Illness (fnILI) Z-Score as a Proxy for Incidence and								
2	Mortality of COVID-19								
3	Running Title: fnILI Z-Score Proxy for COVID-19								
4	Brief Report – Journal of Infectious Disease								
5									
6	Fatima N. Mirza, MPH ¹ , Amyn A. Malik, MBBS, MPH, PhD ^{1,2} , Saad B. Omer, MBBS, MPH,								
7	PhD ^{1,2,3,4}								
8 9 10 11 12	 (1) Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT 06510, USA (2) Yale Institute for Global Health, Yale University, New Haven, CT 06510, USA (3) Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT 06510, USA (4) Yale School of Nursing, Yale University, Orange, CT 06477, USA 								
13	Corresponding Author:								
14 15 16 17 18	1 Church St New Haven, CT 06510 saad.omer@yale.edu Phone: (203) 432-3656								
19	Word Counts:	Abstract: 96/100	Text:	1309/2000					
20 21	References: 9	Figures: 1/1	Tables	s: 1/1					
22									
23									
24									
25									
26									
27									

28 Abstract

29

30	Though ideal for determining the burden of disease, SARS-CoV2 test shortages preclude its
31	implementation as a robust surveillance system in the US. We correlated the use of the derivative
32	influenza-negative influenza-like illness (fnILI) z-score from the CDC as a proxy for incident
33	cases and disease-specific deaths. For every unit increase of fnILI z-score, the number of cases
34	increased by 70.2 (95%CI[5.1,135.3]) and number of deaths increased by 2.1 (95%CI[1.0,3.2]).
35	FnILI data may serve as an accurate outcome measurement to track the spread of the and allow
36	for informed and timely decision-making on public health interventions.
37	
38	Key Words: COVID-19, ILI, CDC, influenza
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	

52 Background

53

54 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread exponentially since

55 December 2019, transforming from a localized outbreak in Wuhan, China to a global pandemic.

56 As of mid-April, roughly 2 million cases have been reported(1), with one-fifth of cases requiring

57 inpatient hospitalization and a case-fatality at an estimated 2%(2).

58

As the number of individuals infected rapidly climbs, the testing capacity has been outpaced by the need for such tests. In the United States, this has posed a challenge to physicians and public health professionals at large, particularly as it relates to accurately tracking the spread of disease. Assessing the intensity of the epidemic nationally in a given region is the backbone of allocating resources at the federal and state level, and inform the implementation or relaxing of public health restrictions (e.g. initiating or easing a lockdown).

65

Given the rapid increase in cases in the previous weeks without parallel expansion in testing capacity and unclear specificity/sensitivity, this problem will only continue to be exacerbated until a nationwide program is made available and further validation studies have been completed (3). In the interim, there is an urgent need to identify proxies for disease incidence that are routinely collected through available infrastructure in the United States in order to guide the evolving public health response in this country(4).

72

73 The Centers for Disease Control and Prevention (CDC) centrally collates data using the U.S.

74 Outpatient Influenza-like Illness Surveillance Network (ILINet) and the National Respiratory

and Enteric Virus Surveillance System (NREVSS) (5). We believe that combining both sources

76 of this publicly-available, routinely collected data may serve as a reliable proxy for SARS-CoV-77 2 incidence and mortality. In this study, we used influenza-negative ILI (fnILI) z-scores and 78 compared them against the reported COVID-19 cases and deaths by week to document trends 79 over time.

80

81 **Methods**

82

We downloaded flu negative influenza-like illness (fnILI) data derived from the Center for 83 84 Disease Control and Prevention's ILINet and NREVSS data for states (5,6). ILINet consists of 85 records from outpatient healthcare providers in all 50 states and reported 60 million patient visits 86 in the 2018-2019 season. Weekly, approximately 2,600 outpatient healthcare providers around 87 the country report the total number of patients as well as those with influenza-like illness, defined as a temperature of 100° F or greater alongside a cough and/or sore throat, as well as 88 89 regional baseline are reported. These data are weighted by state population, and percentage of 90 flu-positive influenza-like illness is compared to regional estimates and a historical nationwide 91 baseline of 2.4%. NREVSS provides virologic surveillance data weekly from approximately 100 92 public health and over 300 clinical laboratories throughout the United States, including the total 93 number of respiratory specimens tested for influenza, the number positive for influenza viruses, 94 and the percent positive by influenza virus type. Some states may have limited data or have 95 delays in reporting that may not make this information immediately available.

96

97 Reich et al (6) reviewed twenty-three seasons of influenza data, beginning in 1997, and ten 98 seasons of statewide data, beginning in 2010 and calculated fnILI from the CDC (5). fnILI was

99

determined using weighted influenza-like illness (wILI) from ILINet – which represents the

percentage of doctor's office visits that presented with a primary complaint of fever and one
 additional influenza-like symptoms – and percentages of positive influenza specimens from
 NREVSS data, compared to a baseline calculated from prior all seasons of data extracted as
 described above. fnILI was calculated as:

$$fnILI = (1 - proportion of tests positive for influenza) x \frac{wILI}{baseline level for ILI}$$

104

These data included a z-score that represents the degree to which a given fnILI observation was
significantly lower or higher than expected based on past trends at similar times during prior
years. Z-score was calculated as:

$$Z = \frac{fnILI - fnILI}{sdfnILI}$$

108

109 with as the average weekly observations for the past nine years with one week on either110 side and as associated standard deviation.

111

112 We merged this dataset with the CDC-reported SARS-CoV-2 cases and disease-specific deaths. 113 We graphically represented the fnILI z-score, cumulative cases, and cumulative deaths for the 114 contiguous U.S for the month of March 2020. We used a mixed effects linear model accounting 115 for clustering at the state level using random effects to determine the relationship between 116 weekly case counts or deaths and fnILI z-score, and a lag term to account for delay between 117 onset of symptoms and confirmation of diagnosis. We selected the model with the lowest Akaike 118 Information Criteria (AIC) and Bayesian Information Criteria (BIC) (7) while maintaining 119 statistical significance. Median fnILI z-score across all states were determined by week and

- 120 plotted against total nationwide cases and/or deaths per week. All data was analyzed using Stata
- 121 v15.0 (StataCorp, College Station, Texas).

122

123 Results

124

125 fnILI data was available for all states except Florida, New Hampshire, New Jersey, and Rhode

126 Island. Over the course of the study period, September 29th 2019 to March 29th 2020, there were

127 123,509 reported COVID-19 cases and 2,303 deaths, representing a case-fatality rate of 1.8%.

128 This represented 36,749,916 unique patient visits across the US with an average of 3,040

129 providers nationwide per week. The rate of fnILI across the study period was 85.8% and the

130 average flu positive baseline across the country was 1.4%.

131

There is an apparent tracking between fnILI z-score and cases or deaths by state over the course
of the study period. This phenomenon is particularly pronounced when comparing these indices
during the month of March (Figure 1A).

135

136 When assessing the correlation over time between fnILI z-score and either new cases or deaths, 137 we observed a z-score peak prior to an increase in cases or deaths. Therefore, we used a lag 138 variable of two weeks for incidence and one week for mortality to better fit the model (Table 1). 139 On the mixed effects linear model accounting for clustering at the state level using random 140 effects, we found that for every unit increase of fnILI z-score two weeks prior, the number of 141 cases increased by 70.2 (95% CI [5.1, 135.3]). Similarly, we found that for every unit increase of 142 fnILI z-score one week prior, the number of deaths increased by 2.1 (95% CI [1.0, 3.2]), also 143 when correcting for regional effects. When plotting the median nation-wide z-score two week or

144	one week prior, respectively, versus new cases (Figure 1B) or deaths (Figure 1C), the two					
145	measures tracked. Nationwide, one unit increase of fnILI z-score correlated with 49243.4 (95%					
146	CI[34250.8, 64235.9]) and 608.3 deaths (95% CI[477.3, 739.4]).					
147						
148	Discussion					
149						
150	There is increasing evidence that current testing may significantly underestimate the burden of					
151	disease (8), necessitating alternative methods to accurately assess these trends over time. Our					
152	results suggest that the fnILI z-score data can be used as a proxy for the trajectory of disease					
153	incidence and mortality in the United States. In the context of limited resources in a rapidly					
154	changing field, it becomes increasingly necessary to innovatively utilize available infrastructure					
155	to tackle the apparent gaps in knowledge quickly. To our knowledge, this is the first academic					
156	study to use fnILI z-scores from ILINet and NVRESS data in order to model and potentially					
157	predict the burden of COVID-19 over time.					
158						
159	This report demonstrates the important potential of such a proxy, and validates its correlation					
160	with incidence and mortality. Importantly, we present the optimal model for such a prediction by					
161	building in a lag term. This two week lag term is likely necessary for incidence due to the known					
162	incubation period of this disease and because of a delay in testing (2). For mortality, our one					
163	week lag term likely represents the rapid escalation to fatality (9). These lag terms also may					
164	allow our model to function as an early warning system for rise in cases, similar to ILINet.					
165						
166	As there is already a robust infrastructure in place to collect these data, validating the use of such					
167	data is extremely valuable, especially in the setting of limited availability and capacity of testing					

- 168 kits. fnILI provides a good proxy in the absence of testing to evaluate the results of public health
- 169 interventions and make timely decisions to change course.

192 Footnote

- 194 Disclosures: The authors have no conflicts of interests to disclose.
- 195 Funding/Support: There is no funding for this study.
- 196 Statement of Prior Presentation: This information has not been previously presented.
- 197 Correspondence and Requests:
- 198 Dr. Saad B. Omer
- 199 1 Church St
- 200 New Haven, CT 06510
- 201 saad.omer@yale.edu
- 202 Phone: (203) 432-3656
- 203
- 204
- 205
- 206
- 207
- 208
- 209
- 210
- 211
- 212
- _
- 213
- 214
- 215

216 **References**

- 217 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
- time. The Lancet Infectious Diseases. Lancet Publishing Group; 2020.
- 219 2. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus
- 220 Disease 2019 in China. N Engl J Med. 2020 Feb 28;
- 221 3. Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbuto V, Veronese N, et al.
- 222 Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative
- 223 Review. Int J Environ Res Public Health [Internet]. 2020 Apr 14 [cited 2020 Apr
- 19];17(8):2690. Available from: https://www.mdpi.com/1660-4601/17/8/2690
- 4. Ienca M, Vayena E. On the responsible use of digital data to tackle the COVID-19
 pandemic. Nat Med. 2020 Mar 27;26(4).
- 5. U.S. Influenza Surveillance System: Purpose and Methods | CDC [Internet]. [cited 2020]

Apr 19]. Available from: https://www.cdc.gov/flu/weekly/overview.htm

229 6. Reich NG, Ray EL, Gibson GC, Cramer E RC. Looking for evidence of a high burden of

230 COVID-19 in the United States from influenza-like illness data. Github. 2020.

- 7. Konishi S, Kitagawa G (Genshiro). Information criteria and statistical modeling. Springer;
 2007.
- 8. Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19
- Antibody Seroprevalence in Santa Clara County, California. medRxiv. 2020 Apr
- 235 17;2020.04.14.20062463.
- 236 9. Jung S, Akhmetzhanov AR, Hayashi K, Linton NM, Yang Y, Yuan B, et al. Real-Time
- 237 Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection:
- 238 Inference Using Exported Cases. J Clin Med. 2020 Feb 14;9(2):523.

239 Tables

240 Table 1. Possible Models for fnILI Z-Score and Incidence or Mortality.

	Incidence	Lag	Coef.	95% CI		р	AIC	BIC
				Lower	Upper			
		None	128.9	79.2	178.6	< 0.01	20516.2	20536.5
		1 Week	129.9	75.5	184.3	< 0.01	19834.7	19854.8
		2 Week	70.2	5.1	135.3	0.03	19095.9	19115.9
		3 Week	1.97	-68.4	72.3	0.9	18364.2	18384
	Mortality	None	2.1	1.1	3.1	< 0.01	11328.3	11348.6
		1 Week	2.1	1.0	3.2	< 0.01	10970.8	10991.0
		2 Week	1.2	-0.08	2.5	0.06	10585.1	10605.1
242								
243								
244								
245								
246								
247								
248								
249								
250								
251								

252 Figure Legend

253

254 Figure 1. Overall state-specific and median nationwide fnILI Z-Score versus COVID-19

- 255 cases or deaths. (A) fnILI z-scores and cumulative cases/deaths for individual states in the
- 256 month of March. (B) Nationwide weekly median fnILI z-scores versus new cases nationwide.
- 257 (C) Nationwide weekly median fnILI z-scores versus deaths nationwide.

258



Z Score fnILI

Cumulative Cases

Cumulative Deaths







